Drug Treatment of Idiopathic Pulmonary Fibrosis Systematic Review and Network Meta-Analysis

被引:150
作者
Canestaro, William J. [1 ]
Forrester, Sara H. [2 ]
Raghu, Ganesh [3 ]
Ho, Lawrence [3 ]
Devine, Beth E. [1 ]
机构
[1] Univ Washington, Sch Pharm, Pharmaceut Outcomes Res & Policy Program, Box 357630,1959 NE Pacific St, Seattle, WA 98195 USA
[2] Univ Washington, Sch Med, Ctr Interstitial Lung Dis, GroupHlth Cooperat, Seattle, WA 98195 USA
[3] Univ Washington, Sch Med, Ctr Interstitial Lung Dis, Div Pulm & Crit Care Med, Seattle, WA 98195 USA
关键词
epidemiology (pulmonary); evidence-based medicine; idiopathic pulmonary fibrosis; meta-analysis; CONTROLLED-TRIAL; PIRFENIDONE; INTERVENTIONS; NINTEDANIB; STATEMENT; EFFICACY;
D O I
10.1016/j.chest.2015.11.013
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a form of chronic progressive fibrosing interstitial lung disease of unknown origin. Recently, nintedanib and pirfenidone demonstrated efficacy in slowing disease progression and were approved by the US Food and Drug Administration. Although numerous treatments have been evaluated in IPF, none have shown significant decreases in mortality. The objective of this study was to identify all pharmacologic treatments evaluated for IPF and analyze their efficacy via Bayesian network meta-analysis and pairwise indirect treatment comparisons. This review did not evaluate the effect of steroid therapy. METHODS: We searched MEDLINE, Embase, and the Cochrane Library for studies published on or before August 2014. Studies were required to contain a randomized evaluation of nonsteroidal drug therapy for treatment of IPF and be published in English. Key outcomes of interest for this analysis were pulmonary function as measured by FVC as well as all-cause and respiratory-specific death. All outcomes were analyzed via a Bayesian framework. RESULTS: Our review identified 30 eligible studies that evaluated 16 unique treatments. Under both the fixed-effect and random-effect models for respiratory-specific mortality, no treatments performed better than placebo. For all-cause mortality, pirfenidone and nintedanib had effects approaching significance with credible intervals slightly crossing the null under a fixed-effect model. Notably, for respiratory-specific mortality, all-cause mortality, and decline in percent predicted FVC, nintedanib and pirfenidone were virtually indistinguishable and no clear advantage was detected. CONCLUSIONS: Although two treatments have been approved for IPF on the basis of reduced decline in pulmonary function, neither one has a clear advantage on mortality outcomes.
引用
收藏
页码:756 / 766
页数:11
相关论文
共 29 条
[1]  
Agapova M, 2014, J COMP EFFECT RES, V3, P345, DOI [10.2217/CER.14.29, 10.2217/cer.14.29]
[2]   Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis [J].
Azuma, A ;
Nukiwa, T ;
Tsuboi, E ;
Suga, M ;
Abe, S ;
Nakata, K ;
Taguchi, Y ;
Nagai, S ;
Itoh, H ;
Ohi, M ;
Sato, A ;
Kudoh, S ;
Raghu, G .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 171 (09) :1040-1047
[3]   General methods for monitoring convergence of iterative simulations [J].
Brooks, SP ;
Gelman, A .
JOURNAL OF COMPUTATIONAL AND GRAPHICAL STATISTICS, 1998, 7 (04) :434-455
[4]  
Brown S, SYST REV
[5]   Evidence Synthesis for Decision Making 2: A Generalized Linear Modeling Framework for Pairwise and Network Meta-analysis of Randomized Controlled Trials [J].
Dias, Sofia ;
Sutton, Alex J. ;
Ades, A. E. ;
Welton, Nicky J. .
MEDICAL DECISION MAKING, 2013, 33 (05) :607-617
[6]   Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis - A randomized prospective study [J].
Douglas, WW ;
Ryu, JH ;
Swensen, SJ ;
Offord, KP ;
Schroeder, DR ;
Caron, GM ;
DeRemee, RA ;
Fisk, DM ;
Krowka, MJ ;
Patel, AM ;
Schwartz, OA .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 158 (01) :220-225
[7]  
du Bois RM, 2011, AM J RESP CRIT CARE, V183, P1231, DOI [10.1164/rccm.201007.1179OC, 10.1164/rccm.201007-1179OC]
[8]   Biomarkers and surrogate endpoints in clinical trials [J].
Fleming, Thomas R. ;
Powers, John H. .
STATISTICS IN MEDICINE, 2012, 31 (25) :2973-2984
[9]   The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations [J].
Hutton, Brian ;
Salanti, Georgia ;
Caldwell, Deborah M. ;
Chaimani, Anna ;
Schmid, Christopher H. ;
Cameron, Chris ;
Ioannidis, John P. A. ;
Straus, Sharon ;
Thorlund, Kristian ;
Jansen, Jeroen P. ;
Mulrow, Cynthia ;
Catala-Lopez, Ferran ;
Gotzsche, Peter C. ;
Dickersin, Kay ;
Boutron, Isabelle ;
Altman, Douglas G. ;
Moher, David .
ANNALS OF INTERNAL MEDICINE, 2015, 162 (11) :777-784
[10]   A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis [J].
King, Talmadge E., Jr. ;
Bradford, Williamson Z. ;
Castro-Bernardini, Socorro ;
Fagan, Elizabeth A. ;
Glaspole, Ian ;
Glassberg, Marilyn K. ;
Gorina, Eduard ;
Hopkins, Peter M. ;
Kardatzke, David ;
Lancaster, Lisa ;
Lederer, David J. ;
Nathan, Steven D. ;
Pereira, Carlos A. ;
Sahn, Steven A. ;
Sussman, Robert ;
Swigris, Jeffrey J. ;
Noble, Paul W. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (22) :2083-2092